Targeting Notch enhances the efficacy of ERK inhibitors in BRAF-V600E melanoma

The discovery of activating BRAF mutations in approximately 50% of melanomas has led to the development of MAPK pathway inhibitors, which have transformed melanoma therapy. However, not all BRAF-V600E melanomas respond to MAPK inhibition. Therefore, it is important to understand why tumors with the...

Descripción completa

Detalles Bibliográficos
Autores principales: Krepler, Clemens, Xiao, Min, Samanta, Minu, Vultur, Adina, Chen, Hsin-Yi, Brafford, Patricia, Reyes-Uribe, Patricia I., Halloran, Molly, Chen, Thomas, He, Xu, Hristova, Denitsa, Liu, Qin, Samatar, Ahmed A., Davies, Michael A., Nathanson, Katherine L., Fukunaga-Kalabis, Mizuho, Herlyn, Meenhard, Villanueva, Jessie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342073/
https://www.ncbi.nlm.nih.gov/pubmed/27655717
http://dx.doi.org/10.18632/oncotarget.12078

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342073/
https://www.ncbi.nlm.nih.gov/pubmed/27655717
http://dx.doi.org/10.18632/oncotarget.12078

Ejemplares similares